nucha

(redirected from nuchal)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to nuchal: nuchal ligament, nuchal arm

nucha

[′nü·kə]
(anatomy)
The nape of the neck.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Association 1 consists of the posterior part of a skull roof including the nuchal plate and partly preserved paranuchal (mostly left one) and central plates (Muz.
Nuchal nevus flammeus as a skin marker of prognosis in alopecia areata.
The nuchal translucency can be visualized using ultrasound in both normal and aneuploidy fetuses, and must be used before 14 weeks gestation as it can no longer be seen by the end of the second trimester and nuchal fold measurement would be required (38,39).
During the spawning season from April to October, mature males may develop a blue nuchal hump anterior to the dorsal fin, making them distinguishable from females and other males (NEFSC (1)).
Previously, first-trimester screening test parameters including nuchal translucency, serum f[beta]-hCG, PAPP-A and ductus venosus were investigated for their associations with adverse perinatal outcomes (1,2,4,5,11).
Here we describe an obliquely striated invertebrate muscle, the nuchal retractor muscle (NRM) of squids and cuttlefishes, which is activated in different ways during locomotion: at the start of muscle shortening, periodically during muscle lengthening, and occasionally during brief periods of muscle isometry.
[6] The symptoms of nuchal pain, and lancinating sensation with loss of power of upper and lower limb muscles indicate atlantoaxial joint disease with bursitis and subluxation of joint due to RA.
Also, NTD's first trimester non-invasive prenatal screening test for Down Syndrome is the only high sensitivity screen that uses the free Beta hCG biomarker, along with PAPP-A and Nuchal Translucency measurement, in assessing risk for Down syndrome.
Pregnant women have traditionally been offered some combination of serum biomarkers and nuchal translucency to assess the risk of fetal aneuploidy.